Analysts Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $25.50

Kura Oncology, Inc. (NASDAQ:KURA) has been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $25.50.

KURA has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. StockNews.com upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating in a report on Friday, April 4th. JMP Securities restated a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a report on Thursday, February 6th. UBS Group reduced their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Finally, Scotiabank lowered their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th.

Insider Buying and Selling at Kura Oncology

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Kura Oncology

A number of hedge funds have recently modified their holdings of the company. FMR LLC raised its stake in shares of Kura Oncology by 26.1% in the third quarter. FMR LLC now owns 86,431 shares of the company’s stock valued at $1,689,000 after purchasing an additional 17,913 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Kura Oncology by 270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,287 shares of the company’s stock valued at $299,000 after buying an additional 11,158 shares during the period. Jane Street Group LLC increased its holdings in Kura Oncology by 36.7% in the 3rd quarter. Jane Street Group LLC now owns 126,085 shares of the company’s stock valued at $2,464,000 after buying an additional 33,848 shares during the period. Barclays PLC raised its stake in shares of Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after buying an additional 84,563 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after acquiring an additional 41,535 shares during the period.

Kura Oncology Price Performance

KURA opened at $5.77 on Wednesday. The stock has a fifty day moving average price of $7.36 and a 200 day moving average price of $10.86. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $23.48. The stock has a market cap of $465.96 million, a price-to-earnings ratio of -2.44 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. Analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.